Last reviewed · How we verify
NCT06138483
A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse
trial in Oropharyngeal Squamous Cell Carcinoma in 267 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Centro di Riferimento Oncologico - Aviano |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 267 |
| Start date | 19 April 2019 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 June 2025 |
| Sites | 5 locations across Italy |
Conditions studied
- Oropharyngeal Squamous Cell Carcinoma — all drugs for Oropharyngeal Squamous Cell Carcinoma →
Sponsor
Centro di Riferimento Oncologico - Aviano
Who can join
18 and older, any sex, with Oropharyngeal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Inclusion of new biomarkers to improve the personalized treatment approach for HPV-positive and -negative oropharyngeal squamous cell carcinoma (OPSCC) patients is urgently needed. Emerging evidences suggest that mutations in epigenetic regulators, as well as epigenetic changes, deeply influence the biology of OPSCC, thus representing attractive targets for the definition of novel molecular markers for this malignancy. Based on these considerations, our project aims to retrospectively identify a new mutational and epigenetic signature to identify OPSCC patients at high risk of early relapse, and to set up a new multicenter prospective study in order to validate it
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06138483
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oropharyngeal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
- NCT06662058 — Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi · NA · recruiting
- NCT06055868 — People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity · recruiting
- NCT06532279 — Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient · Phase 2 · recruiting
- NCT06914999 — Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascula · EARLY_PHASE1 · recruiting
Other Centro di Riferimento Oncologico - Aviano trials
Trials by the same sponsor.
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
- NCT07344363 — Prostate Cancer REsearch Using Cross-validation of Innovative Sampling, Integrating LC-MS/MS for Optimized Therapeutic D · recruiting
- NCT07433777 — Reference Intervals With Indirect Methods in Italy · recruiting
- NCT07374731 — Identification of Biomarkers of Risk for Pre-neoplastic and Neoplastic Lesions for the Development of Gastric Cancer · recruiting
- NCT06738459 — Precision Retrospective Integrative Study for Metastatic Lymph Nodes in Breast Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06138483 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro di Riferimento Oncologico - Aviano
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06138483.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing